BMP7 antagonizes TGF-β-dependent fibrogenesis in mesangial cells

American Journal of Physiology - Renal Physiology

Volumn 284, Issue 5 53-5, 2003, Pages

  Wang, Shinong ^a   Hirschberg, Raimund ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Bone morphogenetic protein 7; Kidney fibrosis; Matrix metalloprotease 2; Plasminogen activator inhibitor 1; Transforming growth factor

Indexed keywords

BONE MORPHOGENETIC PROTEIN; COLLAGEN TYPE 4; FIBRONECTIN; GELATINASE A; MESSENGER RNA; OSTEOGENIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROGENESIS; GENE EXPRESSION; KIDNEY FIBROSIS; MESANGIUM CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0037405422     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00382.2002     Document Type: Article

References (32)

1. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, and Rifkin DB. An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 216: 276-284, 1994.
2. Baricos WH, Cortez SL, Deboisblanc M, and Xin S. Transforming growth factor-β is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 10: 790-795, 1999.
3. Boström K, Tsao D, Shen S, Wang Y, and Demer LL. Matrix GLA protein modulates differentiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells. J Biol Chem 276: 14044-14052, 2001.
4. Bosukonda D, Shih MS, Sampath KT, and Vukicevic S. Characterization of receptors for osteogenic protein-1/bone morphogenetic protein-7 (OP-1/BMP-7) in rat kidneys. Kidney Int 58: 1902-1911, 2000.
5. Briknarova K, Grishaev A, Banyai L, Tordai H, Patthy L, and Llinas M. The second type II module from human matrix metalloproteinase 2: structure, function and dynamics. Structure Fold Des 7: 1235-1245, 1999.
6. Chen Y, Blom IE, Sa S, Goldschmeding R, Abraham DJ, and Leask A. CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int 62: 1149-1159, 2002.
7. Dube P, Frazier K, Charette M, and Paredes A. Osteogenic protein-1 treatment induces tubular regeneration in the acute phase of the rat remnant kidney model (Abstract). J Am Soc Nephrol 8: 614, 1997.
8. Dudley AT, Lyons KM, and Robertson EJ. A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev 9: 2795-2807, 1995.
9. Hegele A, Varga Z, von Knobloch R, Heidenreich A, Kropf J, and Hofmann R. TGF-β1 in patients with renal cell carcinoma. Urol Res 30: 126-129, 2002.
10. Hirschberg R. Bioactivity of glomerular ultrafiltrate during heavy proteinuria may contribute to renal tubulo-interstitial lesions: evidence for a role for insulin-like growth factor I. J Clin Invest 98: 116-124, 1996.
11. Houi K, Kobayashi T, Kato S, Mochio S, and Inoue K. Increased plasma TGF-β1 in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 106: 299-301, 2002.
12. Hruska KA, Guo G, Wozniak M, Martin D, Miller S, Liapis H, Loveday K, Klahr S, Sampath TK, and Morrissey J. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol 279: F130-F143, 2000.
13. Ikeda Y, Jung Y, Kim H, Oda T, Lopez-Guisa J, Wing D, Cai X, McCartney J, and Eddy A. Effects of BMP-7 on interstitial fibrosis in rats with overload proteinuria (Abstract). J Am Soc Nephrol 11: 530A, 2000.
14. Isaka Y, Akagi Y, Ando Y, Tsujie M, Sudo T, Ohno N, Border WA, Noble NA, Kaneda Y, Hori M, and Imai E. Gene therapy by transforming growth factor-β receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 55: 465-475, 1999.
15. Kothapalli D, Frazier KS, Welply A, Segarini PR, and Grotendorst GR. Transforming growth factor β induces anchorage-independent growth of NRK fibroblasts via a connective tissue growth factor-dependent signaling pathway. Cell Growth Differ 8: 61-68, 1997.
16. Lund RJ, Davies MR, and Hruska KA. Bone morphogenetic protein-7: an anti-fibrotic morphogenetic protein with therapeutic importance in renal disease. Curr Opin Nephrol Hypertens 11: 31-36, 2002.
17. MacKay K, Striker LJ, Elliot S, Pinkert CA, Brinster RL, and Striker GE. Glomerular epithelial, mesangial, and endothelial cell lines from transgenic mice. Kidney Int 33: 677-684, 1988.
18. Morrissey J, Hruska K, Guo G, Wang S, Chen Q, and Klahr S. Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol 13, Suppl 1: S14-S21, 2002.
19. Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F, and Brady HR. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 274: 5830-5834, 1999.
20. Nadim M, Rennke H, Taal M, Brenner B, Mackenzie H, and Sayegh M. Bone morphogenetic protein-7 (BMP-7) reduces chronic progressive renal injury in 5/6 nephrectomized rats (Abstract). J Am Soc Nephrol 11: 625A, 2000.
21. Schafer L, Lorenz T, Daemmrich J, Heidland A, and Schaefer RM. Role of proteinases in renal hypertrophy and matrix accumulation. Nephrol Dial Transplant 10: 801-807, 1995.
22. Simon M, Maresh JG, Harris SE, Hernandez JD, Arar M, Olson MS, and Abboud HE. Expression of bone morphogenetic protein-7 mRNA in normal and ischemic adult rat kidney. Am J Physiol Renal Physiol 276: F382-F389, 1999.
23. Singh R, Alavi N, Singh AK, and Leehey DJ. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 48: 2066-2073, 1999.
24. Singh R, Song RH, Alavi N, Pegoraro AA, Singh AK, and Leehey DJ. High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-β1. Exp Nephrol 9: 249-257, 2001.
25. Song CZ, Siok TE, and Gelehrter TD. Smad4/DPC4 and Smad3 mediate transforming growth factor-β (TGF-β) signaling through direct binding to a novel TGF-β-responsive element in the human plasminogen activator inhibitor-1 promoter. J Biol Chem 273: 29287-29290, 1998.
26. Tomooka S, Border WA, Marshall BC, and Noble NA. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 42: 1462-1469, 1992.
27. Wang S, DeNichilo M, Brubaker C, and Hirschberg R. Connective tissue growth factor in tubulo-interstitial injury of diabetic nephropathy. Kidney Int 60: 96-105, 2001.
28. Wang S and Hirschberg R. Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis. Am J Physiol Renal Physiol 278: F554-F560, 2000.
29. Wang S, LaPage J, and Hirschberg R. Loss of tubular bone morphogenetic protein-7 (BMP7) in diabetic nephropathy. J Am Soc Nephrol 12: 2392-2399, 2001.
30. Wilson HM, Reid FJ, Brown PA, Power DA, Haites NE, and Booth NA. Effect of transforming growth factor-β1 on plasminogen activators and plasminogen activator inhibitor-1 in renal glomerular cells. Exp Nephrol 1: 343-350, 1993.
31. Zeisberg M, Strutz F, Mueller G, and Kalluri R. Osteogenic protein-1 (OP-1), an inducer of tubulogenesis in kidney development, mediates anti-fibrogenic effects in vitro (Abstract). Kidney Blood Press Res 23: 227, 2000.
32. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, and Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97: 8015-8020, 2000.